MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
ENDRA Life Sciences Revenue 2011-2026 | NDRA
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue ENDRA Life Sciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 6.17 K | 352 K | 516 K | 1.41 M | 559 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.41 M | 6.17 K | 569 K |
Quarterly Revenue ENDRA Life Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.17 K | - | 287 K | 57.8 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 287 K | 6.17 K | 117 K |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Anixa Biosciences
ANIX
|
210 K | $ 2.85 | -3.72 % | $ 92.5 K |  USA |
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
6.32 B | $ 118.6 | 0.4 % | $ 36.1 B | USA |
 |
Aspira Women's Health
AWH
|
8.18 M | - | -6.19 % | $ 10.5 M | USA |
 |
Fulgent Genetics
FLGT
|
283 M | $ 13.82 | -2.68 % | $ 418 M | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Castle Biosciences
CSTL
|
332 M | $ 27.55 | -1.59 % | $ 765 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 175.77 | -1.61 % | $ 8.71 B | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 108.44 | 0.16 % | $ 8.94 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
4.3 B | $ 635.29 | -0.22 % | $ 51.1 B | USA |
 |
Accelerate Diagnostics
AXDX
|
2.97 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 283.19 | -1.07 % | $ 23.6 B | USA |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
6.79 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 79.15 | 3.74 % | $ 5.34 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
3.18 B | - | - | $ 10.7 B | USA |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 315.61 | -0.56 % | $ 27.1 B |  Schweiz |
|
Biodesix
BDSX
|
71.3 M | $ 15.5 | -1.59 % | $ 2.01 B | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 5.26 | 4.89 % | $ 487 M | USA |
 |
NeoGenomics
NEO
|
727 M | $ 9.53 | 0.26 % | $ 1.22 B | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
National Research Corporation
NRC
|
149 M | $ 13.37 | -3.47 % | $ 328 M | USA |
 |
Natera
NTRA
|
820 M | $ 206.39 | 3.11 % | $ 20.3 B | USA |
 |
Invitae Corporation
NVTA
|
122 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
30.8 M | $ 1.12 | -1.78 % | $ 1.42 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 208.28 | -0.95 % | $ 23.1 B | USA |
 |
Danaher Corporation
DHR
|
24.6 B | $ 204.04 | -0.9 % | $ 145 B | USA |
 |
Organovo Holdings
ONVO
|
144 K | - | -2.3 % | $ 19.4 M | USA |
 |
OPKO Health
OPK
|
184 M | $ 1.22 | -2.02 % | $ 847 M | USA |
 |
Pacific Biosciences of California
PACB
|
160 M | $ 1.51 | -7.1 % | $ 453 M | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | $ 103.38 | 0.02 % | $ 19.5 B | USA |
 |
Bioventus
BVS
|
512 M | $ 8.8 | 0.34 % | $ 551 M | USA |
 |
DarioHealth Corp.
DRIO
|
20.4 M | $ 10.3 | -4.19 % | $ 292 M | Israel |
 |
DexCom
DXCM
|
4.66 B | $ 73.0 | -1.06 % | $ 28.5 B | USA |
 |
PerkinElmer
PKI
|
2.86 B | - | -0.91 % | $ 14.7 B | USA |
 |
Psychemedics Corporation
PMD
|
22.1 M | - | -1.84 % | $ 15.3 M | USA |
 |
Precipio
PRPO
|
15.2 M | $ 24.78 | 0.38 % | $ 32.2 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B |  Niderland |
 |
Quotient Limited
QTNT
|
43.4 M | - | -11.32 % | $ 1.1 M | Schweiz |
 |
Burning Rock Biotech Limited
BNR
|
508 M | $ 24.01 | -4.59 % | $ 254 M | China |
 |
Illumina
ILMN
|
4.37 B | $ 129.9 | -2.25 % | $ 20.7 B | USA |
 |
Renalytix AI plc
RNLX
|
2.29 M | - | 5.66 % | $ 22.7 M | Britain |
 |
VolitionRx Limited
VNRX
|
1.23 M | $ 0.2 | -0.74 % | $ 19.2 M |  Singapore |